Suzhou fujilai Pharmaceutical Co., Ltd
Online roadshow announcement of initial public offering and listing on GEM
Sponsor (co lead underwriter): Orient Securities Company Limited(600958) underwriting sponsor Co., Ltd
Co lead underwriter: Guotai Junan Securities Co.Ltd(601211)
The application of Suzhou fujilai Pharmaceutical Co., Ltd. (hereinafter referred to as “fujilai”, “issuer” or “company”) for initial public offering of no more than 22.92 million ordinary shares (A shares) and listing on the gem (hereinafter referred to as “this offering”) has been examined and approved by the GEM Listing Committee of Shenzhen Stock Exchange (hereinafter referred to as “Shenzhen Stock Exchange”), It has been registered and decided by China Securities Regulatory Commission (zjxk [2022] No. 251).
This issuance adopts directional placement to strategic investors (hereinafter referred to as “strategic placement”) (if any) Offline inquiry placement to qualified investors (hereinafter referred to as “offline issuance”) and online pricing issuance to social public investors holding non restricted A-Shares and non restricted depositary receipts in Shenzhen market (hereinafter referred to as “online issuance”).
The issuer, sponsor (co lead underwriter) Orient Securities Company Limited(600958) underwriting sponsor Co., Ltd. (hereinafter referred to as “China investment bank” or “sponsor (co lead underwriter)”) and co lead underwriter Guotai Junan Securities Co.Ltd(601211) will directly determine the issue price through offline preliminary inquiry, and offline cumulative bidding inquiry will not be conducted. This offering does not arrange strategic placement to other external investors. For example, the offering price exceeds the median and weighted average of offline investors’ quotation after excluding the highest quotation, as well as the Securities Investment Fund (hereinafter referred to as “public fund”) and the National Social Security Fund (hereinafter referred to as “social security fund”) established through public offering after excluding the highest quotation The lower of the median and weighted average of the quoted prices of the basic endowment insurance fund (hereinafter referred to as “pension”), the enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund (hereinafter referred to as “enterprise annuity fund”) and the insurance fund (hereinafter referred to as “insurance fund”) in accordance with the measures for the administration of the use of insurance funds, The relevant subsidiaries of the sponsor (co lead underwriter) of this offering will participate in the strategic placement of this offering in accordance with relevant regulations. The issuer and the co lead underwriters will disclose the information such as the and holding period to the participants in the placement in the announcement on the IPO of Suzhou fujilai Pharmaceutical Co., Ltd. and its listing on the gem.
22.92 million new shares are proposed to be issued to the public, accounting for 25.00% of the total share capital of the company after the issuance. All new shares are issued to the public, and the shareholders of the company will not offer shares to the public. The total share capital after this public offering is 91.67 million shares. Among them, Initial strategic placement (if the issue price exceeds the lower of the median and weighted average of offline investors’ quotations after excluding the highest quotation, and the median and weighted average of public funds, social security funds, pensions, enterprise annuity funds and insurance funds after excluding the highest quotation, the sponsor (co lead underwriter) The alternative investment subsidiary established by the parent company will participate in the strategic placement of this offering in accordance with relevant regulations. The number of shares issued is 1146000, accounting for 5.00% of the number of shares issued this time. The difference between the final placement quantity and the initial placement quantity of strategic investors is transferred back to offline issuance.
Before the launch of the callback mechanism, the initial number of shares issued offline was 15.242 million, accounting for 70% of the number issued after deducting the initial strategic placement; The initial number of shares issued online was 6.532 million, accounting for 30% of the number issued after deducting the initial strategic placement. The total quantity of final offline and online issuance is the total quantity of this issuance minus the final strategic placement quantity. The final offline and online issuance quantity will be determined according to the call back situation. The final offline and online issuance quantity and strategic placement (if any) will be specified in the announcement on the initial public offering of shares by Suzhou fujilai Pharmaceutical Co., Ltd. and the preliminary placement results of offline issuance listed on GEM published on March 21, 2022 (T + 2).
In order to facilitate investors to understand the relevant situation and development prospects of the issuer and the relevant arrangements for the subscription of this issuance, the issuer and the recommendation institution (co lead underwriter) will hold an online roadshow on this issuance. Please pay attention to it.
1. Online roadshow time: 14:00-16:00 on March 16, 2022 (Wednesday, t-1)
2. Online roadshow website: panorama (www.p5w. Net.) Panoramic roadshow (rs.p5w.net.)
3. Participants: key members of the issuer’s management and relevant personnel of the sponsor (co lead underwriter).
The full text of the prospectus and relevant materials can be found on five websites designated by the CSRC (cninfo, www.cn. Info. Com. CN; CSI, www.cs. Com. CN; China Securities, www.cn. Stock. Com; securities times, www.stcn.com; and Securities Daily, www.zqrb. CN) Consult.
Please pay attention to it.
Issuer: sponsor of Suzhou fujilai Pharmaceutical Co., Ltd. (co lead underwriter): Orient Securities Company Limited(600958) underwriting sponsor co lead underwriter: Guotai Junan Securities Co.Ltd(601211) March 15, 2022 (seal page of online roadshow announcement of Suzhou fujilai Pharmaceutical Co., Ltd. on initial public offering and listing on GEM)
Suzhou fujilai Pharmaceutical Co., Ltd. (no text on this page, which is the seal page of the online roadshow announcement of Suzhou fujilai Pharmaceutical Co., Ltd. on initial public offering and listing on GEM)
Orient Securities Company Limited(600958) underwriting and recommendation Co., Ltd. (this page has no text and is the seal page of the online roadshow announcement of Suzhou fujilai Pharmaceutical Co., Ltd. on initial public offering and listing on GEM)
Guotai Junan Securities Co.Ltd(601211) mm / DD / yyyy
